Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES SHARES FOR PAYMENT OF DEBENTURE INTEREST AND REPORTS ON DEBENTURE CONVERSIONS

Ventripoint Diagnostics Ltd. will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange approval. The corporation will issue an aggregate of 291,344 common shares for the payment of an aggregate of $36,989.01 of interest owing on certain outstanding convertible debentures issued by the corporation on June 28, 2024, Dec. 16, 2024, Jan. 17, 2025, and Feb. 7, 2025. The convertible debentures bear interest at the rate of 10 per cent per annum, payable every six months. The shares will be issued at a deemed price of 12.7 cents, subject to the approval of TSX-V, and are subject to a hold period of four months and one day. The issuance of the shares will not create a control person of the corporation.

The debentures issued Jan. 17, 2025, and Feb. 7, 2025, an aggregate of $256,000, have been converted and so no further interest is owing on these series of debentures.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.